Research and Collaborations

We have partnered with collaborators to securely share our scientific data for more than 15 years. It is through these efforts that we have been able to carefully advance our collective understanding of human genomic variation and inherited disease, and responsibly apply genetic technologies in the era of genomics.

ASCO Annual Meeting 2017

  •  

    Peters MLB, et al. Germline Genetic Testing in Unselected Pancreatic Ductal Adenocarcinoma (PDAC) Patients. ASCO 2017, McCormick Place Chicago, IL, June 2-6, 2017 Abstract 
    External Collaboration with Harvard. Ambry authors: Holly LaDuca, Jill S Dolinsky, Emily Dalton, Virginia Speare.
    Abstract Number for Publication: 1501June 5th, 8:12 AM - 8:24 AM

    Kamihara J, et al. Germline mutations in cancer predisposition genes among patients with thyroid cancer ASCO 2017, McCormick Place Chicago, IL, June 2-6, 2017 Abstract
    External Collaboration with Dana-Farber Cancer Institute. Ambry Authors: Holly LaDuca, Emily Dalton, Virginia Speare.
    Abstract Number for Publication: 1581, June 5, 1:15 PM - 4:45 PM

    Horcasitas Dj, et al. Exploring a possible relationship of germline CDKN2A mutations with breast cancer in a multi-gene panel cohort ASCO 2017, McCormick Place Chicago, IL, June 2-6, 2017 Abstract
    External Collaboration with New Mexico Cancer Center. Ambry Authors: Holly LaDuca, Amal Yussuf, Ginger Chisholm, Laura Panos.
    Abstract Number for Publication: e23218

    Fulk K, et al. Comparing actionable results for breast and colorectal cancer patients across multigene panels. ASCO 2017, McCormick Place Chicago, IL, June 2-6, 2017 Abstract
    Abstract Number for Publication: e13109

 

Research Spotlight

  • Mayo Clinic Partners with Ambry in Largest Hereditary Breast Cancer Patient Study to Date

    Breast cancer risks associated with mutations in cancer predisposition genes identified by clinical genetic testing of 60,000 breast cancer patients.

    Fergus Couch, et al. Ambry authors: Robina Smith, Melissa Pronold, Robert Huether, Carin Espenschied, Shuwei Li, Tina Pesaran, Rachel McFarland, Holly LaDuca, Jill Dolinsky
    Quick Take: Mayo Clinic and University of Utah researchers collaborated with Ambry Genetics to study more than 60,000 women diagnosed with breast cancer over a four-year period, with >90% of them meeting National Comprehensive Cancer Network (NCCN®) hereditary breast ovarian cancer (HBOC) testing criteria. All had germline testing using multi-gene panels performed at Ambry. This represents the largest genetic study to date of women with breast cancer, and offers new information about genes that may or may not contribute to breast cancer risk.

 

Stay in the Gnome

 


Click here to view all of our peer-reviewed publications, organized by general topic/product line.

For questions about clinical research or collaborations at Ambry, please fill out the form found here and select "Answer a Question about Research and Collaboration Services."